Research · November 4, 2026

KymaThera's $80M Series B — A Pan-Mutant Bet on PI3Kα, Timed for the Clinic

KymaThera raised an $80 million Series B, led by Alta Partners, to take K-1728, its oral pan-mutant selective PI3Kα inhibitor, into Phase 1 dosing in the fourth quarter of 2026.

What happened

On October 6, 2026, KymaThera, a San Diego biotechnology company developing precision medicines for genetically defined diseases, announced the closing of an $80 million Series B financing. The round was led by Alta Partners, with participation from Venrock and Foresite Capital — the co-leads of KymaThera's 2024 Series A — plus new investor J. Wood Capital and others. The financing brings KymaThera's total capital raised to more than $100 million.

Proceeds will primarily support K-1728, KymaThera's investigational, oral, pan-mutant selective PI3Kα inhibitor. The company expects to begin patient dosing in a Phase 1 study in the fourth quarter of 2026, and says the financing is expected to fund development through initial clinical proof-of-concept. KymaThera is initially developing K-1728 as a monotherapy and in combination regimens for HR+/HER2- breast cancer, and as a monotherapy for PI3Kα-driven vascular malformations — conditions the company describes as serious and often debilitating, with limited systemic treatment options.

The idea: hit every mutant, spare the normal protein

PI3Kα is one of oncology's most validated targets — and one of its most frustrating. The protein's mutant forms drive tumor growth in a meaningful share of breast cancers and in vascular malformations, but the normal, wild-type protein is also doing essential work throughout the body. Earlier generations of PI3Kα inhibitors, in KymaThera's framing, were constrained on both sides: blocking wild-type PI3Kα produced toxicity (notably hyperglycemia), while incomplete coverage of clinically relevant mutations left parts of the disease untouched.

K-1728 is designed to thread that needle. It is built to potently inhibit disease-driving mutations in both the kinase domain and the helical domain of PI3Kα — the two major mutation classes — while sparing wild-type PI3Kα. The molecule was discovered internally by KymaThera using its structure-based drug design platform and is wholly owned by the company. The "pan-mutant" claim is the whole thesis: if one drug can cover the full mutation spectrum without the wild-type toxicity tax, it could serve both a large breast cancer population and a rare-disease population that currently has no systemic option.

The preclinical data the company cites point in that direction, with the usual preclinical caveat. In preclinical and IND-enabling studies, K-1728 showed potent activity against both kinase and helical domain mutations, driving tumor regressions at low, once-daily doses in models harboring both mutation classes. It also demonstrated what the company calls a wide preclinical therapeutic window: a large separation between the drug exposures associated with deep tumor regressions and those associated with hyperglycemia. CEO Rob Kania's version of the claim is specific — "class-leading potency with helical mutant selectivity windows wider than any reported to date" — but it is a company claim about preclinical data, not a clinical result, and the announcement discloses no head-to-head numbers against named competitors.

The people and the money behind it

The syndicate is the signal here as much as the science. Alta Partners leads a round that keeps the entire Series A leadership in place: Venrock and Foresite Capital return as co-leads-turned-participants, joined by J. Wood Capital. Alta partner Bob More's comment — "I invest in people" — is the standard venture framing, but the substance underneath it is a team that took a molecule from internal discovery to a clinic-ready program in about two years since the 2024 Series A, according to Foresite's Michael Rome and Venrock's Mariana Mihalusova. For a preclinical-stage company, execution speed to first-in-human dosing is the credential that matters, and the Q4 2026 dosing target is the date against which that credential will be judged.

The financing structure also tells a story about runway discipline. Eighty million dollars to reach initial clinical proof-of-concept is a defined, single-milestone runway: not enough to commercialize anything, and not meant to be. The next financing — or partnership — will be priced on whatever the Phase 1 data show about safety, exposure, and early signs of activity. That makes the dosing start this quarter the real news inside a three-week-old funding announcement: the round closed the money, but the clinic will start grading the thesis.

What this does not show

The announcement discloses no valuation, no revenue figure (the company is preclinical), no patient count, trial site count, or readout date beyond the Q4 2026 dosing start, and no Series A round size. Efficacy claims are preclinical only; no clinical response, safety, or dosing data exist yet. KymaThera's earlier-stage discovery programs against additional validated targets are named only as a direction, with no targets, timelines, or data disclosed. The comparison to existing PI3Kα-targeting therapies, such as Roche's inavolisib, appears in trade coverage rather than in the company's announcement and is not used here as a company claim.

What would turn this round from a thesis into evidence is the clinical version of the numbers: the Phase 1 safety and exposure profile at doses that matter, whether the wild-type-sparing design actually widens the therapeutic window in patients the way it did in models, and whether activity appears across both mutation classes rather than one. Until dosing starts and data follow, K-1728 remains a well-funded, precisely stated hypothesis about one of oncology's oldest trade-offs.

Sources